

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## **Kangji Medical Holdings Limited**

**康基医疗控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9997)**

### **APPOINTMENT OF EXECUTIVE DIRECTOR AND CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG**

The board (the “**Board**”) of directors (the “**Directors**”) of Kangji Medical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce the following changes with effect from November 5, 2020:

- (i) Ms. Frances Fang CHOVANEC (“**Ms. Chovanec**”) has been appointed as an executive Director; and
- (ii) the principal place of business of the Company in Hong Kong has been changed to Flat 1007B, 10/F, Harbour Crystal Centre, 100 Granville Road, Kowloon, Hong Kong.

#### **APPOINTMENT OF EXECUTIVE DIRECTOR**

The Board announces that, with effect from November 5, 2020, Ms. Chovanec has been appointed as an executive Director. The biographical details of Ms. Chovanec are set out below:

Ms. Chovanec, aged 42, has been served as the chief financial officer of the Company since March 7, 2020 and remains in her current position upon her appointment as an executive Director. Ms. Chovanec has extensive experience in the finance industry and worked at well-known investment banks for more than 12 years. From 2000 through 2014, Ms. Chovanec had successively served as an analyst at JPMorgan Chase & Company, as an associate and then a vice president at Morgan Stanley Asia Limited and an executive director in the investment banking division of Goldman Sachs & Company, where she had extensively involved in investment banking transaction execution and client coverage. From October 2014 to October 2015, Ms. Chovanec served as a director at Teneo Capital, LLC, a company engaged in investment banking, where she focused on M&A transaction execution. From November 2015 to December 2016, Ms. Chovanec was employed as a managing director by Evercore Management Corporation of Fosun Group where she mainly focused on private equity investment and portfolio management. Since January 2017, Ms. Chovanec provided consulting services to clients through her own firm, Bird’s Nest Advisors, LLC, and mainly advised on strategic partnership, licensing and business development projects. One such example was that she served as an executive vice president at TECLens, LLC, a medical device company focusing on the refractive correction market. Ms. Chovanec received her bachelor’s degree in finance from University of Bridgeport in the United States in May 2000 and master’s degree in business administration from the Wharton School of the University of Pennsylvania in the United States in May 2005. Ms. Chovanec is a Chartered Financial Analyst (CFA) and she obtained the qualification from the Chartered Financial Analyst Institute in July 2003.

As of the date of this announcement, Ms. Chovanec is interested in the share options in respect of 4,120,000 underlying shares of the Company granted to her in accordance with the pre-IPO share option plan of the Company adopted on May 6, 2020, representing approximately 0.33% of the total issued share capital of the Company.

Ms. Chovanec has entered into a service contract with the Company for her appointment as an executive Director for a term from the date of this announcement to the date of the next general meeting of the Company. She will be subject to retirement and re-election at the next following general meeting and thereafter subject to retirement by rotation and re-election at annual general meetings of the Company in accordance with the articles of association of the Company. Ms. Chovanec does not receive any remuneration, including director fee, salary, bonus and allowance for her appointment as an executive Director.

Save for the information set out above, as of the date of this announcement, Ms. Chovanec:

- (a) does not hold any other position with the Group;
- (b) does not hold any other directorships in the last three years in public companies, the securities of which are listed on any securities markets in Hong Kong or overseas;
- (c) does not have any other relationships with any Directors, senior management, substantial shareholders or controlling shareholders (the latter two terms as respectively defined in the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”)) of the Company;
- (d) does not have any other interests or is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and
- (e) is not aware of any matters in relation to her appointment that are required to be disclosed pursuant to Rule 13.51 (2) (h) to (v) of the Listing Rules or any matters that need to be brought to the attention of the shareholders of the Company and the Stock Exchange.

The Board believes that the experience and expertise of Ms. Chovanec will assist the Company in its business development in the future. The Board would like to take this opportunity to welcome Ms. Chovanec for joining the Board.

## **CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG**

The Board also announces that the principal place of business of the Company in Hong Kong has been changed to Flat 1007B, 10/F, Harbour Crystal Centre, 100 Granville Road, Kowloon, Hong Kong with effect from November 5, 2020.

By order of the Board  
**Kangji Medical Holdings Limited**  
**ZHONG Ming**  
*Chairman*

Hangzhou, PRC, November 5, 2020

*As at the date of this announcement, the Board comprises Mr. ZHONG Ming, Ms. SHENTU Yinguang and Ms. Frances Fang CHOVANEC as executive Directors; Ms. CAI Li and Mr. CHEN Gang as non-executive Directors; and Mr. JIANG Feng, Mr. GUO Jian and Mr. CHEN Weibo as independent non-executive Directors.*